Drug Delivery Systems for Diabetes Treatment
Само за регистроване кориснике
2019
Аутори
Zarić, BožidarkaObradović, Milan M.
Sudar-Milovanović, Emina
Nedeljković, Jovan
Lazić, Vesna M.
Isenović, Esma R.
Чланак у часопису (Објављена верзија)
,
© 2019 Bentham Science Publishers
Метаподаци
Приказ свих података о документуАпстракт
Background: Insulin is essential for the treatment of Type 1 diabetes mellitus (T1DM) and is necessary in numerous cases of Type 2 diabetes mellitus (T2DM). Prolonged administration of anti-diabetic therapy is necessary for the maintenance of the normal glucose levels and thereby preventing vascular complications. A better understanding of the disease per se and the technological progress contribute to the development of new approaches with the aim to achieve better glycemic control. Objective: Current therapies for DM are faced with some challenges. The purpose of this review is to analyze in detail the current trends for insulin delivery systems for diabetes treatment. Results: Contemporary ways have been proposed for the management of both types of diabetes by adequate application of drug via subcutaneous, buccal, oral, ocular, nasal, rectal and pulmonary ways. Development of improved oral administration of insulin is beneficial regarding mimicking physiological pathway of insulin a...nd minimizing the discomfort of the patient. Various nanoparticle carriers for oral and other ways of insulin delivery are currently being developed. Engineered specific properties of nanoparticles (NP): controlling toxicity of NP, stability and drug release, can allow delivery of higher concentration of the drug to the desired location. Conclusions: The successful development of any drug delivery system relies on solving three important issues: toxicity of nanoparticles, stability of nanoparticles, and desired drug release rate at targeted sites. The main goals of future investigations are to improve the existing therapies by pharmacokinetic modifications, development of a fully automatized system to mimic insulin delivery by the pancreas and reduce invasiveness during admission. © 2019 Bentham Science Publishers.
Кључне речи:
Diabetes type 1 / Diabetes type 2 / delivery systems / insulin / nanoparticles / glucose levelИзвор:
Current Pharmaceutical Design, 2019, 25, 2, 166-173Финансирање / пројекти:
- Хормонска регулација експресије и активности азот оксид синтазе и натријум-калијумове пумпе у експерименталним моделима инсулинске резистенције, дијабетеса и кардиоваскуларних поремећаја (RS-173033)
- Аберације ћелијског циклуса и утицај оксидативног стреса на неуродегенеративне процесе и малигну трансформацију ћелије (RS-173034)
DOI: 10.2174/1381612825666190306153838
ISSN: 1381-6128
PubMed: 30848184
WoS: 000469202300007
Scopus: 2-s2.0-85068112555
Колекције
Институција/група
VinčaTY - JOUR AU - Zarić, Božidarka AU - Obradović, Milan M. AU - Sudar-Milovanović, Emina AU - Nedeljković, Jovan AU - Lazić, Vesna M. AU - Isenović, Esma R. PY - 2019 UR - https://vinar.vin.bg.ac.rs/handle/123456789/8378 AB - Background: Insulin is essential for the treatment of Type 1 diabetes mellitus (T1DM) and is necessary in numerous cases of Type 2 diabetes mellitus (T2DM). Prolonged administration of anti-diabetic therapy is necessary for the maintenance of the normal glucose levels and thereby preventing vascular complications. A better understanding of the disease per se and the technological progress contribute to the development of new approaches with the aim to achieve better glycemic control. Objective: Current therapies for DM are faced with some challenges. The purpose of this review is to analyze in detail the current trends for insulin delivery systems for diabetes treatment. Results: Contemporary ways have been proposed for the management of both types of diabetes by adequate application of drug via subcutaneous, buccal, oral, ocular, nasal, rectal and pulmonary ways. Development of improved oral administration of insulin is beneficial regarding mimicking physiological pathway of insulin and minimizing the discomfort of the patient. Various nanoparticle carriers for oral and other ways of insulin delivery are currently being developed. Engineered specific properties of nanoparticles (NP): controlling toxicity of NP, stability and drug release, can allow delivery of higher concentration of the drug to the desired location. Conclusions: The successful development of any drug delivery system relies on solving three important issues: toxicity of nanoparticles, stability of nanoparticles, and desired drug release rate at targeted sites. The main goals of future investigations are to improve the existing therapies by pharmacokinetic modifications, development of a fully automatized system to mimic insulin delivery by the pancreas and reduce invasiveness during admission. © 2019 Bentham Science Publishers. T2 - Current Pharmaceutical Design T1 - Drug Delivery Systems for Diabetes Treatment VL - 25 IS - 2 SP - 166 EP - 173 DO - 10.2174/1381612825666190306153838 ER -
@article{ author = "Zarić, Božidarka and Obradović, Milan M. and Sudar-Milovanović, Emina and Nedeljković, Jovan and Lazić, Vesna M. and Isenović, Esma R.", year = "2019", abstract = "Background: Insulin is essential for the treatment of Type 1 diabetes mellitus (T1DM) and is necessary in numerous cases of Type 2 diabetes mellitus (T2DM). Prolonged administration of anti-diabetic therapy is necessary for the maintenance of the normal glucose levels and thereby preventing vascular complications. A better understanding of the disease per se and the technological progress contribute to the development of new approaches with the aim to achieve better glycemic control. Objective: Current therapies for DM are faced with some challenges. The purpose of this review is to analyze in detail the current trends for insulin delivery systems for diabetes treatment. Results: Contemporary ways have been proposed for the management of both types of diabetes by adequate application of drug via subcutaneous, buccal, oral, ocular, nasal, rectal and pulmonary ways. Development of improved oral administration of insulin is beneficial regarding mimicking physiological pathway of insulin and minimizing the discomfort of the patient. Various nanoparticle carriers for oral and other ways of insulin delivery are currently being developed. Engineered specific properties of nanoparticles (NP): controlling toxicity of NP, stability and drug release, can allow delivery of higher concentration of the drug to the desired location. Conclusions: The successful development of any drug delivery system relies on solving three important issues: toxicity of nanoparticles, stability of nanoparticles, and desired drug release rate at targeted sites. The main goals of future investigations are to improve the existing therapies by pharmacokinetic modifications, development of a fully automatized system to mimic insulin delivery by the pancreas and reduce invasiveness during admission. © 2019 Bentham Science Publishers.", journal = "Current Pharmaceutical Design", title = "Drug Delivery Systems for Diabetes Treatment", volume = "25", number = "2", pages = "166-173", doi = "10.2174/1381612825666190306153838" }
Zarić, B., Obradović, M. M., Sudar-Milovanović, E., Nedeljković, J., Lazić, V. M.,& Isenović, E. R.. (2019). Drug Delivery Systems for Diabetes Treatment. in Current Pharmaceutical Design, 25(2), 166-173. https://doi.org/10.2174/1381612825666190306153838
Zarić B, Obradović MM, Sudar-Milovanović E, Nedeljković J, Lazić VM, Isenović ER. Drug Delivery Systems for Diabetes Treatment. in Current Pharmaceutical Design. 2019;25(2):166-173. doi:10.2174/1381612825666190306153838 .
Zarić, Božidarka, Obradović, Milan M., Sudar-Milovanović, Emina, Nedeljković, Jovan, Lazić, Vesna M., Isenović, Esma R., "Drug Delivery Systems for Diabetes Treatment" in Current Pharmaceutical Design, 25, no. 2 (2019):166-173, https://doi.org/10.2174/1381612825666190306153838 . .